NASDAQ: ILMN

Illumina's Nonprofit Partner Future Kings Is Cultivating the Next Generation of STEM Leaders

Opening Doors for Students and the Possibilities of a STEM Career
Article

As a middle school math teacher in Woodbridge, Virginia, Dr. Arik King saw firsthand how boys of color trailed their peers in test scores, attendance, and graduation rates—part of an alarming and persistent national trend. Knowing the potential of his students, he designed an after-school program that provided focus and consistent guidance from adult mentors through engaging technology projects.

Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership

Press Release

SAN DIEGO, January 18, 2022 /3BL Media/ -- Illumina Inc. (NASDAQ: ILMN) announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

Illumina Partners With Agendia to Expand Genomic Testing in Breast Cancer Care

Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing and to bring improved insights to patients with breast cancer globally
Press Release

SAN DIEGO, January 12, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) announced a multi-year partnership with Agendia N.V., a world leader in precision oncology for breast cancer, to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina's approach to IVD partnerships in oncology.

Illumina Collaborates With Nashville Biosciences to Accelerate Medicines Development

Collaboration will transform new insights into drug discovery and therapy development through large-scale genomics
Press Release

SAN DIEGO, January 20, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), announced a multi-year agreement to accelerate medicines development through large-scale genomics and the establishment of a preeminent clinico-genomic resource.

Illumina Announces New Innovative Partnerships, Along With New Groundbreaking Technologies at 2022 J.P. Morgan Healthcare Conference

Summary: 

Multiple innovative partnerships with healthcare companies, research institutions, and multiomic developers, along with new groundbreaking technologies, including a new SBS chemistry and long-read capabilities, position Illumina to accelerate genomic adoption and improve human health globally.

Press Release

Multiple innovative partnerships with healthcare companies, research institutions, and multiomic developers, along with new groundbreaking technologies, including a new SBS chemistry and long-read capabilities, position Illumina to accelerate genomic adoption and improve human health globally.

Illumina Enters Co-Development Partnership with SomaLogic to Help Researchers’ Understanding of Biology and Disease

Partnership will Accelerate Next-Generation Sequencing into Fastest-Growing Area of Proteomics Market with Ultra-high Throughput, Ultra-high Plexity Workflow
Press Release

SAN DIEGO, January 6, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan® Proteomics Assay onto Illumina's current and future high throughput next-generation sequencing (NGS) platforms. This partnership accelerates the rapidly growing high throughput sector of the proteomics market.

Illumina Donates Over $14 Million to Local Communities and Volunteers More Than 6,000 Hours in 2021

Multimedia with summary

As we wrap up 2021, we would like to thank our employees for giving back to our communities around the world. Despite the continued challenges of the pandemic, you continued to show up with participation in our giving and volunteering program.

The Illumina Cares program provides giving opportunities and encourages employees to volunteer in their local communities. We match employee donations, offer paid volunteer time off, and support a volunteer rewards program to earn giving dollars for each hour of volunteer work.

Illumina CEO Reflects on the State of Genomics in 2021

Blog

By Francis deSouza

COVID-19 inflicted tremendous suffering in 2021, taking almost 3.5 million lives this year, more than died from HIV/AIDS, tuberculosis and malaria combined last year. We will never forget the loss and pain of this year. But 2021 will also be remembered for the heroic actions of many, and the major medical breakthroughs that were accelerated by the extreme urgency of the pandemic.

Illumina-Supported Startup Uses Tampons to Offer Critical Clues About Women's Reproductive Health

Ridhi Tariyal of NextGen Jane joins a wave of female founders using genomics to drive the FemTech industry
Article

When entrepreneur Ridhi Tariyal walked out of Boston’s Brigham & Women’s Hospital in the fall of 2013, she left feeling frustrated. The first reason was she did not get the information she was seeking; her ob-gyn had told her that was the only place she could find the hormone testing she wanted to evaluate her fertility. (At age 33, Tariyal wasn’t trying to get pregnant; she just wanted reassurance that her reproductive system was in good shape.) She was annoyed that the medical system made it this hard for a woman to find out some basic information about her own body.

JAMA Network Open: How HBCU Used Covid Testing to Keep Campus Open

Delaware State and Testing for America's safety strategy provides model
Press Release

DOVER, Del., December 20, 2021 /3BL Media/ -- A new research study on how frequent COVID testing coupled with other safety measures enabled a historically Black college to safely remain open even as many other universities shut down their campuses has been published Monday by the JAMA Network Open, a member of JAMA Network.

Pages

Subscribe to NASDAQ: ILMN